Healthy Returns: The FDA approved fewer new drugs in 2024 — but some big ones hit the marketCNBC • 01/08/25
This Promising New Alzheimer's Study Could Unlock a Massive Growth Opportunity for Novo Nordisk and Eli LillyThe Motley Fool • 01/08/25
Novo Nordisk Vs. Eli Lilly: Obesity Makes Their Future Bright, But One Of Them Has More PotentialSeeking Alpha • 01/06/25
The Zacks Analyst Blog Eli Lilly, J&J, AbbVie, AstraZeneca and PfizerZacks Investment Research • 01/03/25
Is Eli Lilly Stock A Buy After FDA Pushes Back On Compounded Knockoffs?Investors Business Daily • 01/02/25
Lilly and Novo Went Head-to-Head Over Weight-Loss Drugs in 2024. There's a Clear Winner.Barrons • 12/31/24
Billionaire Philippe Laffont Is Selling Artificial Intelligence Champion Nvidia and Piling Into These Two Industry LeadersThe Motley Fool • 12/29/24